Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Sauer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nature Structural & Molecular Biology|January 8, 2025
Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modificationsTrinity Cookis, Alexandria Lydecker, Paul Sauer, et al.
Biorxiv : the Preprint Server for Biology|February 19, 2024
Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modificationsTrinity Cookis, Alexandria Lydecker, Paul Sauer, et al.
Cancer Cytopathology|October 15, 2013
Conditional prerequisites for microchannel cytologic analysis on wet mount (fluid-based) biopsiesWilfrido Mojica, Rosemary Bassey, Frank Chen, et al.
Journal of Visualized Experiments : Jove|January 15, 2024
Streptavidin-Affinity Grid Fabrication for Cryo-Electron Microscopy Sample PreparationTrinity Cookis, Paul Sauer, Simon Poepsel, et al.
Science (New York, N.Y.)|January 22, 2021
JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modificationsVignesh Kasinath, Curtis Beck, Paul Sauer, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
Vaccine|May 9, 2021
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, et al.
Molecular Pharmaceutics|September 23, 2015
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCsChristopher R Behrens, Edward H Ha, Lawrence L Chinn, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nature Structural & Molecular Biology|January 8, 2025
Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modificationsTrinity Cookis, Alexandria Lydecker, Paul Sauer, et al.
Biorxiv : the Preprint Server for Biology|February 19, 2024
Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modificationsTrinity Cookis, Alexandria Lydecker, Paul Sauer, et al.
Cancer Cytopathology|October 15, 2013
Conditional prerequisites for microchannel cytologic analysis on wet mount (fluid-based) biopsiesWilfrido Mojica, Rosemary Bassey, Frank Chen, et al.
Journal of Visualized Experiments : Jove|January 15, 2024
Streptavidin-Affinity Grid Fabrication for Cryo-Electron Microscopy Sample PreparationTrinity Cookis, Paul Sauer, Simon Poepsel, et al.
Science (New York, N.Y.)|January 22, 2021
JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modificationsVignesh Kasinath, Curtis Beck, Paul Sauer, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
Vaccine|May 9, 2021
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, et al.
Molecular Pharmaceutics|September 23, 2015
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCsChristopher R Behrens, Edward H Ha, Lawrence L Chinn, et al.
Pageof 1